Skip to main content
77°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by RAPT Therapeutics, Inc.
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
August 08, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Reports First Quarter 2024 Financial Results
May 09, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
April 09, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
February 20, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
February 13, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
November 27, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
November 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
November 01, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
October 18, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 30, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
August 11, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
June 07, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 25, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
May 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
March 29, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results
March 14, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Participate in the SVB Securities Global Biopharma Conference
February 07, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
December 08, 2022
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
November 30, 2022
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
November 17, 2022
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
November 17, 2022
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
November 10, 2022
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Tickers
RAPT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.